Adaptimmune Therapeutics PLC
ADAPY· OTC
Filed Aug 8, 2016 · 10-Q · 39 days after period end · 0001104659-16-137807
| Metric | Q2 2016 | Q2 2015 |
|---|---|---|
| Revenue | $328.00K | $2.78M |
| Net Income | -$22.10M | -$14.57M |
| EPS Diluted | -$0.05 | -$0.05 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Adaptimmune Therapeutics PLC · CIK 1621227 · Engraved from SEC EDGAR
ended Jun 30, 2016 · filed Aug 8, 2016 · 39 d after period end